US Patent

US12337002 — Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives

Method of Use · Assigned to Cassiopea SpA · Expires 2028-07-24 · 2y remaining

Vulnerability score 88/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a new enzymatic process for making certain compounds, including a new crystalline form of the active ingredient in the drug Winlevi.

USPTO Abstract

The present invention refers to a new enzymatic process for obtaining 17Î±-monoesters of cortexolone and/or its 9,11-dehydroderivatives starting from the corresponding 17Î±,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to new crystalline forms of cortexolone-17Î±-propionate and 9,11-dehydro-cortexolone 17Î±-butanoate.

Drugs covered by this patent

Winlevi (CLASCOTERONE) · Sun Pharma

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3280`	—	Winlevi

Patent Metadata

Patent number: US12337002
Jurisdiction: US
Classification: Method of Use
Expires: 2028-07-24
Drug substance claim: No
Drug product claim: Yes
Assignee: Cassiopea SpA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.